Table 3.
Characteristic | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
β | P | β | P | β | P | β | P | β | P | β | P | |
Delayed enhancement* | 1.32 | 0.018 | 1.82 | 0.002 | 1.89 | 0.004 | 1.78 | 0.003 | 1.71 | 0.005 | 1.88 | 0.002 |
Male gender* | 1.36 | 0.031 | 1.39 | 0.036 | 1.48 | 0.036 | 1.47 | 0.029 | 1.78 | 0.042 | ||
Age, per year** | -0.01 | 0.74 | ||||||||||
RA duration, per year** | 0.02 | 0.64 | ||||||||||
TNF inhibitor use* | -0.36 | 0.49 | ||||||||||
Framingham risk score, per% | -0.07 | 0.45 | ||||||||||
R2 (†) | 0.31 | 0.49 | 0.50 | 0.50 | 0.51 | 0.51 |
* β coefficients represent the average change in the outcome (DAS28) for those with the characteristic vs. those without.
** β coefficients represent the average change in the outcome (DAS28) per 1 unit increase in the characteristic.
† R2 is the percentage of the total variability in the outcome explained by the aggregate of the predictors in the model.